| Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study EA Carlsen, N Fazio, D Granberg, S Grozinsky-Glasberg, ... Endocrine-related cancer 26 (2), 227-239, 2019 | 163 | 2019 |
| Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors WT Zandee, T Brabander, A Blažević, BLR Kam, JJM Teunissen, ... The Journal of Clinical Endocrinology & Metabolism 104 (4), 1336-1344, 2019 | 146 | 2019 |
| Role of biomarker tests for diagnosis of neuroendocrine tumours J Hofland, WT Zandee, WW de Herder Nature Reviews Endocrinology 14 (11), 656-669, 2018 | 137 | 2018 |
| Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study G Rindi, C Klersy, L Albarello, E Baudin, A Bianchi, MW Buchler, M Caplin, ... Neuroendocrinology 107 (4), 375-386, 2019 | 104 | 2019 |
| Management of carcinoid syndrome: a systematic review and meta-analysis J Hofland, AD Herrera-Martínez, WT Zandee, WW de Herder Endocrine-Related Cancer 26 (3), R145-R156, 2019 | 84 | 2019 |
| The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines WT Zandee, WW de Herder Neuroendocrinology 106 (4), 357-365, 2018 | 82 | 2018 |
| Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE WT Zandee, RA Feelders, DA Smit Duijzentkunst, J Hofland, ... European Journal of Endocrinology 181 (1), 45-53, 2019 | 69 | 2019 |
| Effect of hormone secretory syndromes on neuroendocrine tumor prognosis WT Zandee, K Kamp, RC van Adrichem, RA Feelders, WW de Herder Endocrine-Related Cancer 24 (7), R261-R274, 2017 | 68 | 2017 |
| Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours WT Zandee, K Kamp, RCS van Adrichem, RA Feelders, WW de Herder European Journal of Endocrinology 175 (5), 361-366, 2016 | 61 | 2016 |
| Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours A Blažević, WT Zandee, GJH Franssen, J Hofland, MLF van Velthuysen, ... Endocrine-Related Cancer 25 (3), 245-254, 2018 | 53 | 2018 |
| Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome WT Zandee, T Brabander, A Blažević, NS Minczeles, RA Feelders, ... The Journal of Clinical Endocrinology & Metabolism 106 (9), e3665-e3672, 2021 | 37 | 2021 |
| Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is≥ 10%? E Merola, T Alonso Gordoa, P Zhang, T Al‐Toubah, E Pellè, ... The Oncologist 26 (4), 294-301, 2021 | 34 | 2021 |
| Treatment outcomes of advanced digestive well-differentiated grade 3 NETs L de Mestier, A Lamarca, J Hernando, W Zandee, T Alonso-Gordoa, ... Endocrine-Related Cancer 28 (8), 549-561, 2021 | 30 | 2021 |
| Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines HHG Verbeek, JAA Meijer, WT Zandee, KH Kramp, WJ Sluiter, JW Smit, ... Annals of Surgical Oncology 22, 1207-1213, 2015 | 30 | 2015 |
| Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours WT Zandee, RC van Adrichem, K Kamp, RA Feelders, ... Clinical Endocrinology 87 (2), 165-170, 2017 | 25 | 2017 |
| A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant … ME Noltes, S Kruijff, L Jansen, HE Westerlaan, WT Zandee, R Dierckx, ... EJNMMI research 11, 1-9, 2021 | 21 | 2021 |
| Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging J Refardt, WT Zandee, T Brabander, RA Feelders, GJH Franssen, ... Endocrine-related cancer 27 (11), 615-624, 2020 | 21 | 2020 |
| Evolution of the mesenteric mass in small intestinal neuroendocrine tumours A Blažević, T Brabander, WT Zandee, J Hofland, GJH Franssen, ... Cancers 13 (3), 443, 2021 | 18 | 2021 |
| Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework LD de Hosson, LM van Veenendaal, Y Schuller, WT Zandee, ... Annals of Oncology 28 (12), 3022-3027, 2017 | 18 | 2017 |
| Multidisciplinary integrated care pathway for von Hippel–Lindau disease WPG Wolters, KMA Dreijerink, RH Giles, ANA van der Horst‐Schrivers, ... Cancer 128 (15), 2871-2879, 2022 | 16 | 2022 |
Wouter de HerderProfessor of endocrine Oncology, Erasmus University, ErasmusMC, Rotterdam, the NetherlandsVerified email at erasmusmc.nl